December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Initial results from HOPE-B, the largest phase III study of gene therapy for hemophilia B to date, show etranacogene dezaparvovec yields clinically meaningful levels of factor IX activity within 6 months.